NCT07462468 2026-03-13
A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.
WestVac Biopharma Co., Ltd.
Phase 1 Not yet recruiting
WestVac Biopharma Co., Ltd.
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Shanghai Gynecologic Oncology Group
Aromics Therapeutics